Life Science Connect Podcast

Apple     Spotify     Google


Life Science Connect LSC Podcast
Special Edition #2: Biopharma And The Management Of Wall St. During A Pandemic
Three CEOs of publicly traded biopharmaceutical companies discuss how they are leading their organizations, while also managing the expectations of Wall St. during the COVID-19 pandemic.  Continue Reading..
  • Special Edition #1: Leadership During COVID-19 — A Biopharma CEO Roundtable

    Five biopharmaceutical industry CEOs discuss challenges their company's have faced, along with best practices implemented in managing through the COVID-19 chaos.

  • 027: Announcing Our Special Edition Series

    Starting in April, we will be releasing the audio portion of our popular Executive Virtual Roundtables.

  • 026: Vaccine Advancements & The Future Outlook

    BioprocessOnline editor Matt Pillar discusses the current vaccine market, some advancements that have been made, and if its growth is sustainable. 

  • 025: Are Decentralized Trials Finally Here To Stay?

    Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways. Our guest, editor, Ed Miseta, weighs in on this timely topic.

  • 024: Perceptions Of A Virtual JPM

    Life Science Leader Chief Editor Rob Wright has attended numerous JPM conferences, so he gives his feedback on how this year’s virtual show compared to previous years.

  • 023: What’s Hot In Gene Therapy

    Erin Harris, chief editor of, reviews some of the hot cell & gene topics for 2020 and what to watch for in 2021. She also discusses the upcoming Cell & Gene Live event and the miniseries she did for the Business of Biotech podcast. 

  • 022: Not Your Same Old CDMOs

    2020 seems to be the year of the evolution of the atypical, newfangled CDMO. Pharma outsourcing editor Louis Garguilo talks about this trend and what makes these new models all the rage. 

  • 021: A Bio Outlook Preview & A Podcast Review

    Today’s guest, Matt Pillar, not only hosts two of his own podcasts, but is our Chief Editor for BioProcess Online. Matt gives a peek into what trends he wrote about for the Life Science Leader outlook issue, and he talks about what’s next for his Business of Biotech podcast.

  • 020: The Golden Age Of Biosimilars? Really?

    It was only a little more than a year ago when the phrase “throw in the towel” was being used in reference to the biosimilars industry. Now, some say we’re in the “Golden Age” of biosimilars. Anna Rose Welch tries to explain to Dan why the big flip. 

  • 019: An Executive Order & PhRMA’s Response Spur A Debate

    Our guest, Outsourced Pharma Chief Editor Louis Garguilo, talks about the response from readers — and PhRMA — to his editorial, “Is PhRMA’s White House Rebuttal Acceptable?”

  • 018: The Unusual Backstory Of The MiMedx Cover Feature

    Ever wonder how a pharma executive gets to be on the cover of Life Science Leader? For Tim Wright, CEO of MiMedx, it was a chance encounter at a leadership conference a few years ago.

  • 017: Is Puerto Rico The Answer To U.S. Pharma Manufacturing?

    Louis Garguilo elaborates on his recent editorial regarding the immense opportunity that Puerto Rico offers —and has offered for years — pharma manufacturers looking to bring back operations to the states.

  • 016: Can A Biosimilars Shared Savings Model Work In The U.S.?

    Anna Rose Welch talks about a new whitepaper that explains why now is the best time for a U.S.  biosimilars shared savings model.

  • 015: Virtual Conferences: Are You Getting Value From Them?

    Virtual conferences are here to stay ... for awhile at least. Rob Wright gives some of his pros and cons regarding these events based on his first-hand experiences these past few months.

  • 014: More Cell & Gene Jobs For Philly

    Cell & Gene Chief Editor Erin Harris talks about a new study that predicts a dramatic rise in jobs for the cell and gene sector in Philadelphia and what’s driving that change. 

  • 013: Show Me The Data!

    Our biosimilars expert, Anna Rose Welch, talks about a new peer-reviewed paper that strongly suggests we “re-think biosimilar development following today’s regulatory science.

  • 012: What’s Next: AC Immune & Video Interviews

    Life Science Leader Chief Editor Rob Wright talks about why he chose AC Immune for an upcoming feature article and the evolution of the new video roundtables with top pharma execs. 

  • 011: “Attending” The DIA Conference...From Your Couch

    Ed Miseta of Clinical Leader talks about how the upcoming DIA conference is going to be different -- and the same -- and he gives details on the virtual CRO Leadership Awards.

  • 010: Editorial Prompts Reader Feedback … And More Questions

    One provocative article about reducing our reliance on foreign sources for drug development leads to some strange feedback, which leads to some additional intriguing articles.

  • 009: Pitching Investors In A Virtual World

    Our guest Rob Wright talks about his conversations with a biotech startup that allowed him to review their pitch deck in preparation for some potential investor meetings.

  • 008: Biosimilars, Videos, And A Cat Named Honeypenny

    Anna Rose Welch, Chief Editor of Biosimilar Development, discusses her foray into making videos for LinkedIn (along with her cat) and the state of the biosimilars industry, including some upcoming conferences.

  • 007: Our Work Life In A COVID-19 World

    Rob Wright, Chief Editor of Life Science Leader magazine, discusses the many changes that have occurred in his job and the jobs of some of our pharma subscribers due to the COVID-19 pandemic. He also discusses one reader’s unique idea regarding some inspiring stories that have cropped up during this current crisis. 

  • 006: The Pharma Supply Chain Is Holding Up…So Far

    What has the coronavirus outbreak taught us about the pharmaceutical supply chain? A lot, and some of it’s not good, according to our guest today, Louis Garguilo, Chief Editor of Outsourced Pharma.

  • 005: The Coronavirus Plan Is Flawed

    Bioprocess Online Chief Editor Matt Pillar gives some background on his provocative new article, “Is Biopharma's Response To Coronavirus Off The Mark?” He also discusses his feature story, “The Perilous Development of a Potential Biologic Blockbuster,” and why it’s one of the most read articles on his site.

  • 004: Glimpse Into A Cell & Gene Outlook

    Cell & Gene Chief Editor Erin Harris is the guest on the podcast today. She discusses some of the top names on her editorial advisory board and gives a glimpse into the 2020 outlook articles that the board has been authoring. 

  • 003: Dealing With A S#*tstorm

    Life Science Leader Chief Editor Rob Wright gives a behind-the-scenes look at his upcoming feature articles on Blueprint Medicines and Arrowhead Pharmaceuticals as well as an intriguing question submitted to his editorial board.

  • 002: Focus On Patients

    On today’s episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials.

  • 001: The JPM Conference

    In this episode, Life Science Leader magazine Chief Editor Rob Wright talks about what he learned while attending this year’s JPM Conference and some of the other peripheral life sciences events that go on in San Francisco during early January.


Life Science Connect Editorial Director, Dan Schell, works with a talented and passionate group of editors who cover a broad spectrum of the pharmaceutical and biotech industries. For the Life Science Connect podcast, he sits down with them to have an informal discussion about some of the hot topics they’re writing about, interesting interviews they’ve had recently with top industry executives, and what they learned during their recent travels to trade shows and conferences. His rotating cast of contributors includes Life Science Connect editors Rob Wright, Ed Miseta, Louis Garguilo, Anna Rose Welch, Erin Harris, and Matt Pillar.